For patients undergoing hysterectomy or myomectomy for benign uterine tumors, minimally invasive gynecologic surgery (MIGS) has the advantages of fewer complications and faster recovery time compared with traditional laparotomy. Morcellation techniques, which are used to pulverize the uterus or myoma, facilitate the implementation of MIGS, especially for women with large uteruses or myomas or who are nulliparous. However, the safety of morcellation techniques has been controversial since the US Food and Drug Administration (FDA) issued a warning in 2014. The main concern is that unprotected morcellation may spread tissue fragments throughout the abdominal cavity. If a malignancy is present, such as uterine leiomyosarcoma (uLMS)-a highly invasive tumor that is difficult to diagnose preoperatively-this spread can have catastrophic consequences. The 5-year disease-specific survival rate for patients with uLMS who undergo unprotected morcellation is only 25.3%, while the 5-year disease-specific survival rate for patients who undergo complete tumor resection is 62.6%. Although the FDA recommends the use of tissue containment systems during laparoscopic morcellation, implementation of this recommendation varies worldwide, and endobag devices (tissue protection bags) are not universally available. Therefore, the management of peritoneal uLMS that disseminate after unprotected morcellation remains a major clinical challenge.

Hyperthermic intraperitoneal chemotherapy (HIPEC) is an important method for the treatment of peritoneal disseminated tumors. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown efficacy in the treatment of peritoneal carcinomatosis in gastrointestinal and ovarian cancers. Recent studies have reported that it can significantly improve progression-free survival (PFS) and overall survival (OS) rates in patients with recurrent uLMS with peritoneal metastasis. A meta-analysis of 13 cases of recurrent uLMS conducted by Matsuzaki et al. in 2021 showed that the 3-year progression-free survival (PFS) and overall survival (OS) rates of patients who received CRS-HIPEC were 71.4% and 75.0%, respectively, compared with 0% and 50.1% for patients who received CRS alone. However, the efficacy and safety of this treatment for patients with accidentally comminuted uLMS remain uncertain.

In 2016, Sun Yat-sen Memorial Hospital of Sun Yat-sen University established a HIPEC program to routinely perform tumor reduction surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for patients with comminuted uLMS. Due to the limited availability of the HIPEC program outside our center, the HIPEC PROGRAM registry system was established to help refer patients from external institutions and receive CRS-HIPEC treatment. This study will conduct a retrospective study through the registration system, with patients who underwent unprotected morcellation surgery for occult uLMS and received CRS-HIPEC treatment as the research subjects, with progression-free survival (PFS) and overall survival (OS) as the primary outcomes, and the incidence of HIPEC-related ≥ grade 3 adverse events (AEs) as the secondary outcome, to evaluate the efficacy and safety of CRS-HIPEC as the first-line treatment for accidentally morcellated uLMS.